Ryzodeg® (insulin degludec and insulin aspart) (NN5401)

:Type 1 and 2 diabetes
:Filed for registration

A soluble co-formulation of Tresiba®, the new-generation basal insulin analogue with an ultra-long duration of action, and NovoRapid® (insulin aspart, marketed as NovoLog® in the US), a rapid-acting mealtime insulin. Approved to offer patients reduced risk of hypoglycaemia. Approved in the EU, Japan and other markets. Additional data required by the US FDA are being generated for the planned resubmission.

Company announcements
Increased operating profit by 18% in the first quarter of 2013 (01 May 2013)
Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg® (10 Feb 2013)
Novo Nordisk increased operating profit by 32% in 2012 (31 Jan 2013)
Read more company announcements

Press releases
Novo Nordisk reported to the police by the Danish Financial Supervisory Authority for violating disclosure obligation (10 Dec 2013)
Ryzodeg® offers improved glycaemic control with significantly lower rates of hypoglycaemia compared to biphasic insulin aspart 30 in adults with type 2 diabetes1 (03 Dec 2013)
New study demonstrates efficacy throughout 2.5 years for Tresiba® (24 Sep 2013)
Read more press releases

Scientific abstracts

No scientific abstracts matching the search criteria


You can search for more clinical trials on http://clinicaltrials.gov
  •